Bavarian Nordic Seeks Brazilian Approval for Chikungunya Vaccine
Event summary
- Bavarian Nordic's partner Eurofarma submitted a marketing authorization application for the CHIKV VLP chikungunya vaccine to Brazil's Anvisa on July 13, 2026.
- The submission targets approval for individuals aged 12 and older in Brazil, a country heavily impacted by chikungunya.
- Eurofarma holds exclusive distribution rights for the vaccine in Brazil under a January 2026 agreement with Bavarian Nordic.
- CHIKV VLP is already approved in the U.S., Europe, UK, Switzerland, and Canada under the brand name VIMKUNYA®.
The big picture
This submission marks a critical step in Bavarian Nordic's strategy to transition from travel-market vaccines to addressing endemic disease burdens. Brazil's high chikungunya case load—over half of global reported cases and deaths—makes it a strategic priority for both Bavarian Nordic and its local partner Eurofarma. The success of this regulatory push could set a precedent for similar filings in other Latin American countries.
What we're watching
- Regulatory Timeline
- The pace at which Anvisa reviews the submission will determine when the vaccine becomes available in Brazil.
- Market Expansion
- Whether Eurofarma can leverage its first-refusal rights to expand the vaccine's reach beyond Brazil into Latin America.
- Competitive Dynamics
- How Bavarian Nordic's strategic focus on endemic regions will position it against competitors in the chikungunya vaccine space.
Related topics